Class / Patent application number | Description | Number of patent applications / Date published |
514656000 | Polycyclo ring system | 52 |
20160107982 | NOVEL CHEMICAL COMPOUNDS DERIVED FROM NORMEMANTINE AND USE OF SAME IN THE MEDICAL FIELD - The present invention concerns novel chemical compounds corresponding to formulae (I) and (II): (I) (II) which, when marked with fluorine-18, can be used as markers of NMDA receptors for carrying out studies with a scanner. | 04-21-2016 |
514657000 | Bicyclo ring system | 51 |
20080269348 | Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use - The invention provides novel arylbicyclo[3.1.0]hexylamines, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including but not limited to depression and anxiety. | 10-30-2008 |
20080280993 | Treatment of CNS Disorders With trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine - Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful. | 11-13-2008 |
20080287550 | Sertraline hydrochloride form II and methods for the preparation thereof - The present invention is directed to Form II of sertraline hydrochloride and novel methods for its preparation. According to the present invention, sertraline hydrochloride Form II may be produced directly form sertraline base or sertraline mandelate. It may also be produced from sertraline hydrochloride solvate and hydrate forms, and crystallized from new solvent systems. Pharmaceutical compositions containing sertraline hydrochloride Form II and methods of treatment using such pharmaceutical compositions are also disclosed. | 11-20-2008 |
20080306163 | AGENT FOR TREATMENT OF ALLERGIC EYE DISEASE - An agent for the treatment of allergic eye disease containing a 3-anilino-2-cycloalkenone derivative having the formula (I): | 12-11-2008 |
20090062399 | DEUTERIUM-ENRICHED SERTRALINE - The present application describes deuterium-enriched sertraline, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-05-2009 |
20090062400 | Method of treating glaucoma using rasagiline - Disclosed is a method of reducing glaucoma in a subject afflicted with glaucoma, comprising administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptably salt thereof effective to reduce glaucoma. | 03-05-2009 |
20090111892 | Rasagiline Orally Disintegrating Compositions - This invention provides a solid pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt of rasagiline, and particles having a non-filamentous microstructure of at least two sugar alcohols. This invention also provides a solid pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt of rasagiline, a mixture of a disintegrant, a flow agent and particles having a non-filamentous microstructure of at least two sugar alcohols, a supplemental sugar alcohol, a supplemental flow agent, and a supplemental disintegrant. This invention further provides a method of treating a subject afflicted with Parkinson's disease comprising administering to the subject a therapeutically effective amount of the solid pharmaceutical composition, thereby treating the subject. Finally, this invention provides a process of making such solid pharmaceutical compositions. | 04-30-2009 |
20090131535 | PROPARGYLAMINO INDAN DERIVATIVES AND PROPARGYLAMINO TETRALIN DERIVATIVES AS BRAIN-SELECTIVE MAO INHIBITORS - The subject invention provides derivatives of propargylamino indan (PAI) and propargylamino tetralin that selectively inhibit monoamine oxidase (MAO) in the brain, having the structure: | 05-21-2009 |
20090149549 | PREPARATION OF CHIRAL AMIDES AND AMINES - This invention provides a convenient method for converting oximes into enamides. The process does not require the use of metallic reagents. Accordingly, it produces the desired compounds without the concomitant production of a large volume of metallic waste. The enamides are useful precursors to amides and amines. The invention provides a process to convert a prochiral enamide into the corresponding chiral amide. In an exemplary process, a chiral amino center is introduced during hydrogenation through the use of a chiral hydrogenation catalyst. In selected embodiments, the invention provides methods of preparing amides and amines that include the 1,2,3,4-tetrahydro-N-alkyl-1-naphthalenamine or 1,2,3,4-tetrahydro-1-naphthalenamine substructure. | 06-11-2009 |
20090258949 | AMORPHOUS FORM OF CINACALCET - The present invention relates to dispersions of stable amorphous cinacalcet hydrochloride in a matrix material, methods for the preparation thereof, and pharmaceutical compositions comprising said dispersions. | 10-15-2009 |
20090292026 | Treatment of CNS Disorders With trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine - Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful. | 11-26-2009 |
20090312436 | Rasagiline for parkinson's disease modification - A method for modifying Parkinson's disease by periodically administering a pharmaceutical composition comprising a therapeutically effective amount of rasagiline or a pharmaceutically acceptable salt of rasagiline to the patient, thereby modifying the disease. The method includes reducing the rate of progression; delaying the need for symptomatic anti-Parkinsonian therapy; reducing the risk of a Parkinson's disease patient requiring symptomatic anti-Parkinsonian therapy; and reducing the functional decline. | 12-17-2009 |
20090318564 | Process for preparing and drying solid rasagiline base - Disclosed is crystalline R(+)-N-propargyl-l-aminoindan containing water at an amount of less than 0.5% by weight and a pharmaceutical composition comprising the same, and the process for the manufacture and the validation thereof. Also disclosed is a process for the preparation of solid rasagiline base. | 12-24-2009 |
20100010098 | POLYMORPHS OF RASAGILINE HYDROCHLORIDE - A polymorph of rasagiline hydrochloride displays improved stability and is useful in forming pharmaceutical compositions for treating Parkinson's disease. Another polymorph is useful as an intermediate in forming the stable crystalline form. | 01-14-2010 |
20100069504 | AMINOBENZOCYCLOHEPTENE DERIVATIVES, METHODS FOR PREPARING THE SAME AND USES THEREOF IN THERAPY - A compound of the general formula (I) as an active principle for treating cancer, specifically tumors, in particular diseases involving inhibition of metalloproteases, such as Aminopeptidase-N. Pharmaceutical compositions comprising the compound of general formula (I). Methods of treatment using the compound of general formula (I). | 03-18-2010 |
20100137447 | METHOD FOR THE PRODUCTION OF ADSORBATES OF A RASAGILINE SALT HAVING A WATER-SOLUBLE ADJUVANT - The present invention relates to an adsorbate of a pharmaceutically compatible rasagiline salt comprising at least one pharmaceutically compatible adjuvant, wherein the at least one pharmaceutically compatible adjuvant is a water-soluble, organic solvent and the rasagiline salt is present in the adsorbate as an amorphous substance. | 06-03-2010 |
20100144887 | Crystalline solid rasagiline base - The subject invention provides crystalline R(+)-N-propargyl-1-aminoindan, pharmaceutical compositions and methods of manufacture thereof. | 06-10-2010 |
20100227934 | THERAPEUTIC COMPOUNDS AND METHODS OF USE - The invention relates to protein binding interacting/binding compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating 5-HT2C disorders, including diseases and disorders mediated by GPCRs. | 09-09-2010 |
20110015274 | FORM OF AN AMINOINDAN MESYLATE DERIVATIVE - The present disclosure relates generally to rasagiline mesylate with improved flowability and with advantageously reduced stickiness, to processes for the preparation thereof, and to the use thereof for milling and for preparing pharmaceutical formulations. Methods for improving the flowability and/or alleviating the stickiness of rasagiline mesylate having a very poor flowability and/or showing undesirable stickiness are also disclosed. | 01-20-2011 |
20110028564 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES - The invention features compositions, methods, and kits useful for the treatment of filovirus-mediated diseases, e.g., hemorrhagic fever caused by Ebola virus, in an animal. | 02-03-2011 |
20110105622 | PHARMACEUTICAL COMPOSITION CONTAINING GLUR2-LACKING AMPAR ANTAGONIST FOR PREVENTING OR TREATING PSYCHIATRIC ILLNESSES - A pharmaceutical composition, comprising a GluR2-lacking AMPAR antagonist as an active ingredient, is effective for preventing or treating mental diseases selected from the group consisting of posttraumatic stress disorder (PTSD), drug addiction, and phobia. | 05-05-2011 |
20110130466 | USE OF RASAGILINE FOR THE TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY - A method for the treatment of Progressive Supranuclear Palsy. Such method includes administering to a subject an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof. | 06-02-2011 |
20110152381 | 3-KETO-N-PROPARGYL-1-AMINOINDAN - The subject invention provides a pharmaceutical composition containing N-propargyl-1(R)-aminoindan or a pharmaceutically acceptable salt thereof, and a compound of 3-keto-N-propargyl-1-aminoindan or a salt thereof. | 06-23-2011 |
20110184071 | PROCESS FOR THE PREPARATION OF AMINES - The present invention relates to an improved process for the preparation of rasagiline (1) and its pharmaceutically acceptable salts. In particular it relates to a process for preparing rasagiline (1) and its salts substantially free from impurities. | 07-28-2011 |
20110251288 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE AMINES - The present invention relates to an improved process for the preparation of (R)-1-aminoindan (2), rasagiline (1) and pharmaceutically acceptable salts of rasagiline. | 10-13-2011 |
20110263719 | POLYMORPHIC FORM OF RASAGILINE MESYLATE - The present invention relates to a novel crystalline form of rasagiline mesylate and a pure form of rasagiline mesylate and processes for their preparation. Further, the invention relates to pharmaceutical compositions comprising said forms and use of said compositions in the treatment of patients suffering from Parkinson's Disease, dementia, Alzheimer's Disease, depression, hyperactive syndrome, stroke, brain ischemia, neurotrauma, schizophrenia and multiple sclerosis. | 10-27-2011 |
20110281953 | PROCESS FOR PREPARING AND DRYING SOLID RASAGILINE BASE - Disclosed is crystalline R(+)-N-propargyl-1-aminoindan containing water at an amount of less than 0.5% by weight and a pharmaceutical composition comprising the same, and the process for the manufacture and the validation thereof. Also disclosed is a process for the preparation of solid rasagiline base. | 11-17-2011 |
20110281954 | METHODS OF SYNTHESIZING CINACALCET AND SALTS THEREOF - Methods of preparing cinacalcet, cinacalcet derivatives, and salts thereof is disclosed herein. Also disclosed herein are polymorphs of cinacalcet, compositions of cinacalcet, and methods of treating a subject by administering cinacalcet, wherein cinacalcet is prepared by the disclosed methods. | 11-17-2011 |
20110313050 | SOLID COMPOSITION CONTAINING THE INGREDIENT RASAGILINE - The present invention relates to a solid composition containing at least one pharmaceutically compatible auxiliary ingredient and rasagiline or a pharmaceutically compatible salt thereof as an active ingredient. The invention further relates to a method for producing said solid composition and to a medicine comprising said solid composition. | 12-22-2011 |
20120029087 | USE OF RASAGILINE FOR THE TREATMENT OF OLFACTORY DYSFUNCTION - Disclosed are methods of treating olfactory dysfunction by periodically administering a therapeutically effective amount of rasagiline or a pharmaceutically acceptable salt of rasagiline to a subject. | 02-02-2012 |
20120095106 | PREPARATION OF CHIRAL AMIDES AND AMINES - This invention provides a convenient method for converting oximes into enamides. The process does not require the use of metallic reagents. Accordingly, it produces the desired compounds without the concomitant production of a large volume of metallic waste. The enamides are useful precursors to amides and amines. The invention provides a process to convert a prochiral enamide into the corresponding chiral amide. In an exemplary process, a chiral amino center is introduced during hydrogenation through the use of a chiral hydrogenation catalyst. In selected embodiments, the invention provides methods of preparing amides and amines that include the 1,2,3,4-tetrahydro-N-alkyl-1-naphthalenamine or 1,2,3,4-tetrahydro-1-naphthalenamine substructure. | 04-19-2012 |
20120095107 | METHODS FOR TREATMENT OF CARDIOVASCULAR DISORDERS AND DISEASES - Propargylamine, propargylamine derivatives including N-propargyl-l-aminoindan, enantiomers and analogs thereof, and pharmaceutically acceptable salts thereof, are useful for prevention or treatment of cardiovascular disorders, diseases and conditions. | 04-19-2012 |
20120101168 | DEUTERIUM ENRICHED RASAGILINE - The subject invention provides deuterated rasagiline, its salts and uses. | 04-26-2012 |
20120136065 | Treatment of CNS Disorders with trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine - Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful. | 05-31-2012 |
20120208892 | EMESIS TREATMENT - A method of treating or preventing emesis through the administration of an effective dosage of a 2-(amino) tetralin compound in which one of the S or R enantiomers of the 2-(amino) tetralin compound is present in the composition in excess of the other enantiomer, and compositions comprising such a 2-(amino) tetralin compound in which the ratio of the S and R enantiomers is at least 2:1. | 08-16-2012 |
20120214877 | STABLE RASAGILINE COMPOSITION - The present invention provides a stable composition of rasagiline comprising an effective dosage of rasagiline or its pharmaceutically acceptable salts and an antioxidant used as a stabilizer. The dosage forms of the composition are pharmaceutically common transdermal-drug delivery dosage form and mucoadhesive delivery dosage form, such as patch, gel, ointment, cream, cataplasm, film, spray and solution, etc. The composition can be used to prevent or treat mental disorders. | 08-23-2012 |
20120238636 | RASAGILINE ORALLY DISINTEGRATING COMPOSITIONS - This invention provides a solid pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt of rasagiline, and particles having a non-filamentous microstructure of at least two sugar alcohols. This invention also provides a solid pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt of rasagiline, a mixture of a disintegrant, a flow agent and particles having a non-filamentous microstructure of at least two sugar alcohols, a supplemental sugar alcohol, a supplemental flow agent, and a supplemental disintegrant. This invention further provides a method of treating a subject afflicted with Parkinson's disease comprising administering to the subject a therapeutically effective amount of the solid pharmaceutical composition, thereby treating the subject. Finally, this invention provides a process of making such solid pharmaceutical compositions. | 09-20-2012 |
20130158125 | Treatment of CNS Disorders with trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine - Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful. | 06-20-2013 |
20130345310 | SOLID COMPOSITION CONTAINING THE INGREDIENT RASAGILINE - The present invention relates to a solid composition containing at least one pharmaceutically compatible auxiliary ingredient and rasagiline or a pharmaceutically compatible salt thereof as an active ingredient. The invention further relates to a method for producing said solid composition and to a medicine comprising said solid composition. | 12-26-2013 |
20140051767 | PARENTERAL FORMULATIONS OF RASAGILINE - This application provides a method of preferentially inhibiting monoamine oxidase A (MAOA) in the brain of a subject relative to in the intestine of the subject comprising parenterally administering to the subject a controlled release formulation comprising a therapeutically effective amount of rasagiline or a pharmaceutically acceptable salt thereof. | 02-20-2014 |
20140051768 | METHOD OF TREATING DISEASES THAT RESPOND TO THERAPY BY DOPAMINE OR DOPAMINE AGONISTS - The invention relates to a medicament containing (S)-2-N-propylamino-5-hydroxytetralin, the salts or prodrugs thereof. As a D3 agonist, (S)-2-N-propylamino-5-hydroxytetralin is suitable particularly for the treatment of dopa-sensitive movement disorders. | 02-20-2014 |
20140057990 | PREPARATION OF CHIRAL AMIDES AND AMINES - This invention provides a convenient method for converting oximes into enamides. The process does not require the use of metallic reagents. Accordingly, it produces the desired compounds without the concomitant production of a large volume of metallic waste. The enamides are useful precursors to amides and amines. The invention provides a process to convert a prochiral enamide into the corresponding chiral amide. In an exemplary process, a chiral amino center is introduced during hydrogenation through the use of a chiral hydrogenation catalyst. In selected embodiments, the invention provides methods of preparing amides and amines that include the 1,2,3,4-tetrahydro-N-alkyl-1-naphthalenamine or 1,2,3,4-tetrahydro-1-naphthalenamine substructure. | 02-27-2014 |
20140121284 | Stable Pharmaceutical Composition - Provided is a stable pharmaceutical composition having as an active ingredient a therapeutically effective amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof, an absorption modulator, and a diluent, wherein the absorption modulator is glycerin, and the diluent is anhydrous dibasic calcium phosphate (CaHPO | 05-01-2014 |
20140128474 | TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPTHALENAMINE - Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful. | 05-08-2014 |
20140163115 | Migraine Treatments using the Bone Homeostasis Drug Cinacalcet - A novel pathogenesis underlying certain types of seizures and migraines is disclosed and the validated set of premises presented enable the deductive conclusion to be made that drugs that reduce the amount of calcium ions (Ca++) released from bone reduce seizure and migraine risk. The premises validated as true in the specifications include:
| 06-12-2014 |
20140243418 | RASAGILINE FOR PARKINSON'S DISEASE MODIFICATION - A method for modifying Parkinson's disease by periodically administering a pharmaceutical composition comprising a therapeutically effective amount of rasagiline or a pharmaceutically acceptable salt of rasagiline to the patient, thereby modifying the disease. The method includes reducing the rate of progression; delaying the need for symptomatic anti-Parkinsonian therapy; reducing the risk of a Parkinson's disease patient requiring symptomatic anti-Parkinsonian therapy; and reducing the functional decline. | 08-28-2014 |
20140364506 | DEUTERIUM ENRICHED RASAGILINE - The subject invention provides deuterated rasagiline, its salts and uses. | 12-11-2014 |
20150031774 | RASAGILINE ORALLY DISINTEGRATING COMPOSITIONS - This invention provides a solid pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt of rasagiline, and particles having a non-filamentous microstructure of at least two sugar alcohols. This invention also provides a solid pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt of rasagiline, a mixture of a disintegrant, a flow agent and particles having a non-filamentous microstructure of at least two sugar alcohols, a supplemental sugar alcohol, a supplemental flow agent, and a supplemental disintegrant. This invention further provides a method of treating a subject afflicted with Parkinson's disease comprising administering to the subject a therapeutically effective amount of the solid pharmaceutical composition, thereby treating the subject. Finally, this invention provides a process of making such solid pharmaceutical compositions. | 01-29-2015 |
20150045445 | 3-KETO-N-PROPARGYL-1-AMINOINDAN - The subject invention provides a pharmaceutical composition containing N-propargyl-1(R)-aminoindan or a pharmaceutically acceptable salt thereof, and a compound of 3-keto-N-propargyl-1-aminoindan or a salt thereof. | 02-12-2015 |
20160022572 | METHODS, COMPOSITIONS AND DEVICES FOR TREATMENT OF MOTOR AND DEPRESSION SYMPTOMS ASSOCIATED WITH PARKINSON'S DISEASE - Compositions, methods and devices for intranasal administration of Rasagiline or a pharmaceutically acceptable salt thereof are disclosed. The compositions, devices and methods are for treating depression, Parkinson's disease and/or motor and depression symptoms associated with Parkinson's disease, by intranasal administration of an amount of Rasagiline or a pharmaceutically acceptable salt thereof that is sufficient to inhibit depressive illness in the subject and/or is sufficient to inhibit MAO-A in the brain of a subject. | 01-28-2016 |
20160145194 | THERAPEUTIC COMPOUNDS AND METHODS OF USE - The invention relates to protein binding interacting/binding compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating 5-HT2C disorders, including diseases and disorders mediated by GPCRs. | 05-26-2016 |